期刊文献+

vWF及GPIb在慢性肾脏疾病中变化及作用

Effect of von Willebrand factor and GPIb in chronic kidney diseases
下载PDF
导出
摘要 目的研究假性血管血友病因子(vWF)及血小板膜糖蛋白Ib(GPIb)在慢性肾脏疾病(CKD)不同阶段的变化及意义。方法87例患者按病因及CKD不同阶段分为5组,A组:CKD1期,肾小球肾炎组,17例;B组:CKD1期,原发性肾病综合征组,14例;C组:CKD1期,继发性肾病组,18例;D组:CKD2~4期,慢性肾衰组,18例;E组:CKD5期,慢性肾衰透析组,20例。酶联免疫吸附检测法测定GPIb、双抗体夹心固相酶免疫测定血浆vWF。结果vWF、GPIb在A、B、C、D、E组均明显增高,以B、C组尤为突出;与凝血状况正相关。结论vWF水平可同时反应内皮细胞受损及凝血状态,在肾小球疾病发展中可能有重要意义。 Objective To investigate the chamges of vWF and GPIb levels in different stages of chronic kidney disease(CKD). Method 87 cases (male 49, female 38) were divided into five groups: (1) Glomerulonephritis in CKD stage 1 (group A, 17 cases), (2) Nephroitic syndrome in CKD stage 1 (group B, 14 cases), (3) Secondary nephrosis in CKD stage 1 (group C, 18 cases) ; (4) Chronic renal failure in CKD stage 2-4 (group D, 18 cases), (5) Chronic renal failure undergoing heonodialysis in CKD stage 5 (group E, 20 cases), vWF (von Willebrand factor) and GPIb were detected by bivanlent antibody sandiwich assay and ELISA respectivel. Results vWF and GPIb levels were significantly elevated in group A, B, C D, E. especially in group B and C. and closely related to coagulation status. Conclusions vWF and GPIb may, at least in part, play important role in the development of chronic kidney disease.
出处 《临床肾脏病杂志》 2007年第6期266-268,共3页 Journal Of Clinical Nephrology
关键词 假性血管血友病因子 血小板膜糖蛋白 慢性肾脏疾病 von Willebrand factor GPIb Chronic kidney disease
  • 相关文献

参考文献2

二级参考文献22

  • 1孙林,叶任高,李幼姬,陈康联,于黔.系膜增殖性肾炎患者肾生存率的研究[J].中华肾脏病杂志,1996,12(6):359-362. 被引量:18
  • 2Ono, T, Kanatau K, Doi T, et al. Relationship of intraglomerular coagulation and platelet aggregation to glomerular sclerosis. Nephron, 1991,58: 429 - 436.
  • 3Deguchi F, Tomura S, Yoshiyama N, et al. Intraglome rular deposition of coagulation - fibrinolysis factors and a platelet membrane antigen in various glomerular diseases.Nephron , 1989, 51:377 - 383.
  • 4Drojewski Z, Nowak J, Raszeja - Specht A. et al.Evaluation of platelet membrane structure in patients with chronic glomerulonephritis. Przegl Lek, 1996, 53:431 - 433.
  • 5Peerschke EI, Recognition of platelet - associated fibrinogen by polyclonal antibodies: correlation with platelet aggregation. Blood, 1992, 79:2028 - 2033.
  • 6Rupprecht HD Schocklmann HO, Sterzel RB.Cell -matrix interactions in the glomerular mesangium. Kidney Iht , 1996, 49 . 1575 - 1582.
  • 7Zheng DQ, Fornaro M, Bofetiado CJM, et al, Modulation of cell proliferation by the integrin cytoplasmic domain.Kidney Int, 1997, 51:1434~ 1440.
  • 8Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreasde shear- induced platelet aggregation mediated by decreased availability of glycoprotein Iib- Ⅲa receptors.Am J Kidney Dis, 1996,27:355 - 36 .
  • 9Tassies D, Reverter JC, Cases A, et al. Ret; ciculated platelets in uremic patients: effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol,1995, 50 : 161 - 166.
  • 10Yoshida E, Fujimura Y, Ikeda Y, et al. Impaired high -shear- stress - induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis. Br J Haematol, 1995, 89:861 - 867.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部